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A rrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited myocardial disease char-
acterized by fibrofatty degeneration and aneurysmal 
enlargement of the right ventricle (RV).  This condition 
is associated with exercise-mediated ventricular tachy-
cardia and is one of the recognized causes of sudden 
cardiac death.  Sudden cardiac arrest (CA) is one of the 
major causes of death worldwide.  The diagnosis and 
prevention of CAs is a major challenge.  Bystander-
witnessed CA accounts for an estimated 19,000 cases in 
Japan.  The reported 1-month survival rate of sudden 
CA is 12.2%,  and the survival rate without neurological 
sequelae is 7.9% [1].  ARVC is estimated to have a prev-
alence of 1 in 5,000 people and to account for up to 20% 
of sudden cardiac deaths in the population of individu-
als < 35 years of age [2].  ARVC was first reported over 
30 years ago,  but despite its clinical importance as a 
cause of sudden death,  it is still under-recognized.  This 
report describes the case of a middle-aged man who 
recovered from a CA without neurological sequelae and 
was diagnosed with ARVC.
Case Report
A 61-year-old Japanese man presented with palpita-
tions and edema of the lower limbs.  The electrocardio-
gram (ECG) showed rhythms suggestive of atrial fibril-
lation,  and echocardiography revealed severe mitral 
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Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetically mediated cardiomyopathy charac-
terized by progressive myocardial loss of the right ventricle and its replacement by fibrofatty tissue, causing 
dyskinesia, aneurysm, and/or arrhythmia.  The prevalence of ARVC is estimated to be 1 in 2,000-5,000, with the 
condition accounting for up to 20% of sudden cardiac deaths in individuals < 35 years old.  This report describes 
the case of 61-year-old Japanese who was diagnosed with ARVC after cardiac arrest (CA) and successful resusci-
tation.  After the sudden CA, the restoration of spontaneous circulation was achieved with appropriate resusci-
tation, followed by the introduction of target temperature management in the intensive care unit.  He was diag-
nosed with ARVC based on angiography and histology results.  An ICD (implantable cardioverter-defibrillator) 
was implanted, and he was discharged without neurological sequelae 1 month post-CA.  ARVC is an important 
cause of sudden CA, and successfully resuscitated patients with right ventricular dilation should undergo testing 
to rule out ARVC.
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regurgitation and a left ventricular ejection fraction 
(LVEF) of 16%.  The right atrium (RA) and right ventri-
cle (RV) were also dilated without aneurysmal change,  
i.e.,  the RV outflow tract (prox.) was 39 mm,  the basal 
RV diameter was 39 mm,  and the mid-RV diameter 
was 44 mm.  The patient underwent ablation therapy 
and was administered amiodarone 200 mg daily.  The 
dose of amiodarone was gradually reduced to 100 mg 
after 14 months and was stopped after 20 months.  The 
LVEF gradually improved to 48%.
Six months after the cessation of amiodarone,  the 
patient suddenly experienced a CA while playing golf 
outdoors.  Basic life support was immediately per-
formed by a bystander,  and an automated external 
defibrillator (AED) was applied.  The AED monitor 
showed a wide QRS wave and “R on T” followed by VT,  
and subsequently AED was performed twice.  
Restoration of spontaneous circulation (ROSC) was 
achieved upon the patient’s admission to the hospital,  
and the ECG findings indicated an incomplete right 
bundle branch block (RBBB),  first-degree AV block,  
and inverted T-waves in leads V4-V6 (Fig. 1).
A two-dimensional echocardiography (2D-echo) 
examination was performed and revealed dilation of the 
RV and diffuse hypokinesis of the left ventricle (LV) 
wall; the LVEF was 45%,  and both atria were dilated.  
No significant regurgitation was observed,  and the tri-
cuspid regurgitation pressure gradient (TR-PG) was 15 
mmHg (Fig. 2).
The results of coronary angiography were normal,  
and RV angiography showed ventricular dilatation and 
regional dyskinesia (Fig. 3).  In electrophysiology stud-
ies,  VTs were reproducibly induced by a program of 
stimulation of the RV apex or the outflow tract.  When 
pilsicainide was administered,  Brugada syndrome,  QT 
prolongation syndrome,  and catecholaminergic poly-
morphic ventricular tachycardia were absent.  Cardiac 
magnetic resonance imaging (MRI) demonstrated typi-
cal dilation of the right atrium and ventricle.  The ven-
tricular wall was isointense on T1-weighted MRI and 
hyperintense on T2-weighted MRI.  There was no evi-
dence of late gadolinium enhancement.  As these results 
suggested that the patient had ARVC,  a right anterior 
myocardial biopsy was performed,  and it revealed that 
ventricular myocytes were replaced by adipose and 
fibrous tissues (Fig. 4).
The patient was treated with target temperature 
management in the ICU,  after which full recovery of 
consciousness was achieved.  During his hospital stay,  
100 mg of amiodarone was administered daily.  The 
patient was transferred to another hospital for implant-
able cardioverter-defibrillator (ICD) implantation 
12 days after admission,  with no neurological sequelae.
Discussion
Despite its importance as a cause of sudden CA,  
ARVC is not widely known to clinicians.  It is manda-
tory that all patients who are resuscitated following a 
CA and who have right ventricular dilatation undergo 
RV angiography and a myocardial biopsy,  and their 
family history should be determined appropriately.
The prevalence of ARVC varies among different eth-
nicities and is estimated to be between 1 in 2,000 to 1 in 
5,000 individuals [3 , 4].  Right ventricular dilation and 
inverted T-waves (V1-V3) are keys to the diagnosis of 
ARVC.  Inverted T-waves reflecting abnormal right ven-
tricular repolarization are seen during the early stages of 
ARVC.
ARVC was first reported in a case series in 1982 by 
Marcus et al.  [5].  It is a cardiomyopathy characterized 
by right ventricular dilation and dysfunction and ven-
tricular arrhythmias of right ventricular origin.  
Pathologically,  fibrofatty scar tissue progresses mainly 
from the epicardial side to the endocardial side of the 
RV,  causing thinning and dilatation of the ventricular 
wall [6].  Fibrofatty scar tissue that replaces normal 
myocardial tissue delays intraventricular conduction 
and becomes a substrate for arrhythmia through a mac-
ro-reentry mechanism,  and this contributes to the 
development of ventricular arrhythmia,  similar to that 
observed after a myocardial infarction [7].
The diagnosis of ARVC is based on the criteria of the 
International Task Force for the Clinical Diagnosis of 
ARVC [8].  The findings in the present case that met the 
international criteria were as follows: regional RV dys-
kinesia with a reduced right ventricular ejection frac-
tion detected by echocardiography,  MRI,  and angiog-
raphy findings; < 50% residual myocytes estimated by 
fibrous replacement in RV free-wall myocardial sam-
ples; inverted T-waves in the right precordial leads;  
sustained ventricular tachycardia with a left bundle 
branch block; and the superior axis pattern.
The estimated mortality rate for ARVC varies among 
studies and ranges from 0.08% to 3.6% of cases per year 
[9].  The prognosis of patients with ARVC depends 
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strongly on the residual cardiac function and the sever-
ity of the arrhythmia [9-12].  Recent cohort studies have 
shown that well-diagnosed and treated patients and 
their families have good prognoses [13-15].  Since 
ARVC is a cardiomyopathy resulting from ventricular 
arrhythmias with impaired cardiac function,  the goal of 
patient management is to alleviate these symptoms,  
reduce the risk of sudden cardiac death,  and improve 
the quality of life [16].  Ventricular arrhythmias in par-
ticular cause sudden cardiac death and thus require 
strict prevention and management.  Sports activities can 
increase the risk of sudden cardiac death in ARVC 
patients [6 , 17],  as lethal arrhythmias could develop 
August 2021 A Successful Course of CA Due to ARVC 519
A B
Fig.  2　 Apical four-chamber view (A) and short-axis view (B) 
showing the dilated right ventricle.
A B
Fig.  4　 A,  Right ventricular free-wall myocardium at hematoxylin 
and eosin staining shows the fibrous replacement (red arrow) and 
fatty replacement (black arrow) of myocyte tissue; B,  RV free-wall 
myocardium shows fibrous replacement (arrow) (Masson trichrome 
staining).
A B
Fig.  3　 Diastolic (A) and systolic (B) right ventricular 
angiography showing ventricular dilatation and regional dyskinesia.
A
B
Fig.  1　 A,  “R on T” followed by ventricular tachycardia on the AED monitor at the pre-hospitalization facility (arrow); B,  Post-
electrical cardioversion 12-lead electrocardiogram showing complete right bundle branch block,  paroxysmal ventricular compression,  and 
T-wave inversion (arrows).
during such activities.
This patient was not diagnosed with ARVC when 
examined at the pre-hospitalization facility.  After 
admission to our hospital,  ablation and amiodarone 
therapy were provided,  and the patient’s cardiac func-
tion then improved.  Catheter ablation is sometimes 
performed for VT associated with ARVC.  Nogami et al.  
reported that ablation of the isolated delayed compo-
nent significantly reduces the recurrence rate of 
arrhythmias [18].  However,  since many VT substrates 
appear in patients with ARVC due to disease progres-
sion,  the frequency of arrhythmia recurrence increases 
over time,  and there is no strong evidence that ablation 
effectively prevents sudden cardiac death [19-23].  In 
fact,  VT can recur several years after ablation,  even in 
the present case.
Amiodarone is used for the treatment of VT.  
Amiodarone is an effective antiarrhythmic drug that is 
either prescribed alone or together with a beta-blocker,  
and the combination provides both the class III antiar-
rhythmic effects of amiodarone and beta-adrenergic 
blockade [24-26].  However,  long-term treatment with 
amiodarone is challenging due to its severe cumulative 
toxic effects,  such as pulmonary fibrosis,  especially in 
younger patients.  In the present case,  amiodarone was 
discontinued based on the good clinical course,  but 
6 months later,  the patient developed ventricular 
arrhythmias leading to the CA.  This coincided with the 
time point at which the patient’s blood concentration of 
amiodarone decreased,  indicating that amiodarone was 
effective in suppressing VT in this patient.  The patient 
resumed amiodarone treatment after his admission to 
the hospital.
The use of an ICD has been effective in ARVC 
patients who have episodes of lethal arrhythmia.  
Randomized controlled trials of defibrillation therapy 
have not yet been conducted; however,  observational 
studies have consistently shown safe and effective results 
of ICDs [11 , 12 , 15 , 24 , 25 , 27].  An ICD should be con-
sidered essential in ARVC patients who have been suc-
cessfully resuscitated,  as in the present case [28].  The 
patient underwent ICD transplantation 2 weeks after his 
resuscitation from lethal arrhythmia and is alive with-
out major adverse events > 6 months later.
In conclusion,  it is necessary to test for ARVC and 
perform appropriate interventions in resuscitated 
patients with right ventricular dilatation.
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